Αρχική World News Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced... World News Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC Από Ogkologos - 13 Απριλίου, 2026 364 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Indications for Durvalumab 27 Ιουλίου, 2020 An existing blood test for ovarian cancer has been re-evaluated. The... 28 Οκτωβρίου, 2020 What to Say to Someone With Cancer: A Patient Perspective 14 Ιουλίου, 2022 FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Mantle Cell Lymphoma 11 Ιουνίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched... ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory... Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced...